Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
The latest announcement is out from SciSparc Ltd. ( (SPRC) ).
SciSparc Ltd. has received renewed approval from the Israeli Medical Cannabis Agency for its clinical trial of SCI-210, a treatment for autism spectrum disorder in children. This trial, conducted at Soroka University Medical Center, aims to assess the efficacy and safety of SCI-210 compared to standard CBD treatment. The company’s efforts in ASD research could potentially lead to innovative treatment options and future commercialization in Israel and internationally.
More about SciSparc Ltd.
SciSparc Ltd. is a clinical-stage pharmaceutical company specializing in cannabinoid-based therapies for central nervous system disorders. The company is engaged in developing treatments for conditions like Tourette Syndrome, Alzheimer’s disease, autism, and status epilepticus, with a focus on leveraging THC and non-psychoactive cannabidiol. SciSparc also has a controlling interest in a business selling hemp seed oil products on Amazon.
YTD Price Performance: -90.47%
Average Trading Volume: 4,636,432
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $4.82M
For detailed information about SPRC stock, go to TipRanks’ Stock Analysis page.
